As a clinical strategy of preventing the development of trastuzumab-induced cardiotoxicity, Wu et al. [8] recently investigated and reported the clinical efficacy and attenuation of trastuzumab-induced cardiac dysfunction in HER2-positive breast cancer patients using fixed 440 mg dose monthly administration of trastuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.